Iranian Intensive Care Unit (ICU) Glutamine Study

Iranian Intensive Care Unit (ICU) Glutamine Study

This is a double-blinded placebo-controlled block randomized study in intensive care patients comparing enteral glutamine supplementation to placebo. The hypothesis is an improvement of clinical and paraclinical outcomes. The primary endpoint is Infection Probability Score (IPS) and Systemic Inflammatory Response Syndrome (SIRS). Anthropometric measures and serum inflammatory mediators will be compared.

Inclusion Criteria:

• Age 18-60
• No corticosteroids use
• No history of heart, liver and kidney diseases
• Nutrition through nasogastric or orogastric

Exclusion Criteria:

• Patients who will not tolerate enteral nutrition for more than 48 hours
• Patients who are NPO and nutritional support has not started
• Lactating and pregnant women
• Kidney failure during the study
• A history of glutamin supplement use before the study